Related references
Note: Only part of the references are listed.Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study
Luc Cabel et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2018)
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma
Robert J. Motzer et al.
ONCOLOGIST (2017)
VE-cadherin RGD motifs promote metastasis and constitute a potential therapeutic target in melanoma and breast cancers
Ruben A. Bartolome et al.
ONCOTARGET (2017)
A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib
Clive Stubbs et al.
ANTICANCER RESEARCH (2017)
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
Maeva Dufies et al.
BRITISH JOURNAL OF CANCER (2017)
Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring
Dhanusha Sabanathan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Microenvironmental regulation of tumour angiogenesis
Michele de Palma et al.
NATURE REVIEWS CANCER (2017)
Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
Pauline Rochefort et al.
BRITISH JOURNAL OF CANCER (2017)
Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas
Maeva Dufies et al.
CANCER RESEARCH (2017)
Neovascularity as a prognostic marker in renal cell carcinoma
Tyler M. Bauman et al.
HUMAN PATHOLOGY (2016)
Antitumour actions of interferons: implications for cancer therapy
Belinda S. Parker et al.
NATURE REVIEWS CANCER (2016)
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux
Sandy Giuliano et al.
AUTOPHAGY (2015)
Serum and Urine Biomarkers for Human Renal Cell Carcinoma
A. L. Pastore et al.
DISEASE MARKERS (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Dynamic phosphorylation of VE-cadherin Y685 throughout mouse estrous cycle in ovary and uterus
Adama Sidibe et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2014)
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
B. Escudier et al.
BRITISH JOURNAL OF CANCER (2014)
Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
Robert J. Motzer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: Characterization of sorafenib-resistant cells derived from a cutaneous metastasis
Takashi Karashima et al.
INTERNATIONAL JOURNAL OF UROLOGY (2013)
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1
Teresa Di Desidero et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Evidence for Post-Translational Processing of Vascular Endothelial (VE)-Cadherin in Brain Tumors: Towards a Candidate Biomarker
Isabelle Vilgrain et al.
PLOS ONE (2013)
Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: Evidence for tumor necrosis factor α-induced VE-cadherin cleavage
Adama Sidibe et al.
ARTHRITIS AND RHEUMATISM (2012)
Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
Roger B. Cohen et al.
INVESTIGATIONAL NEW DRUGS (2012)
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
Chrisostomi Gialeli et al.
FEBS JOURNAL (2011)
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
Sylvie Negrier et al.
LANCET ONCOLOGY (2011)
Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma
Dan Huang et al.
CANCER RESEARCH (2010)
Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma
Benoit Blanchet et al.
CLINICA CHIMICA ACTA (2009)
The Control of Vascular Integrity by Endothelial Cell Junctions: Molecular Basis and Pathological Implications
Elisabetta Dejana et al.
DEVELOPMENTAL CELL (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors
Namali T. Fernando et al.
CLINICAL CANCER RESEARCH (2008)
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
Naeem Bhojani et al.
EUROPEAN UROLOGY (2008)
Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells
Harriet M. Kluger et al.
LABORATORY INVESTIGATION (2008)
Mechanisms of disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC
Robert A. Figlin
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site
Y. Wallez et al.
ONCOGENE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Anti-angiogenic effects of SN38 (active metabolite of irinotecan):: inhibition of hypoxia-inducible factor 1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells
H Kamiyama et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues
N Lambeng et al.
CIRCULATION RESEARCH (2005)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
